H uman killer cell Ig-like receptors (KIRs) are transmembrane glycoproteins expressed on natural killer (NK) cells that detect the expression levels of major histocompatibility complex (MHC) class I on normal and diseased cells (1) (2) (3) . In humans, KIR genes are divided into inhibitory type (2DL and 3DL) and activating type (2DS, 3DS, and 2DL4), which are receptors with two or three C2-type Ig-like extracellular domains (4) (5) (6) . Whereas the human leukocyte antigen (HLA)-ligand specificities for inhibitory KIRs are relatively well studied, with available structural information for three KIR-DL-HLA complexes, the ligands for activating KIRs are not well-defined and no KIR-DS-HLA complexes have been described (7, 8) . We report here the structure of the activating KIR2DS2 in complex with HLA-A*11:01 and a vaccinia viral peptide. The solved structure at 2.5-Å resolution reveals that Tyr45, which is a residue specific to KIR2DS2, forms a hydrogen bond with the backbone of the HLA α1-helix at Thr80 and contributes to the binding specificity of KIR2DS2-A*11:01. This is a distinct departure from the inhibitory KIRs that use position 44, which engages the dimorphic HLA-C1 (Asn80) or HLA-C2 (Lys80) epitope of HLA-C. These data provide a detailed description of the unique features that characterize the binding of an activating KIR and its cognate HLA ligand.
Results
Crystal Structure of the KIR2DS2-HLA-A*11:01 Complex. Human KIRs have been reported to bind HLAs that carry a selective range of epitopes including C1, C2, Bw4, and A3/A11 (1, 9) . Crystal structures of KIR2DL1-C*04:01 (10), KIR2DL2-C*03:04 (11) , and KIR3DL1-B*57:01 (12) in complex with their respective HLA ligands are available, but there is as yet none for activating KIRs. The activating KIR 2DS2 is an interesting KIR that has been associated with NK responses and susceptibility to cytomegalovirus (13) , hepatitis C virus (14) , and ulcerative colitis (15) . It has very close sequence similarity to KIR2DL2 and KIR2DL3, differing only in four and two amino acid residues, respectively, and, despite having only these few substitutions, binding to HLA-C was abrogated (16, 17) . KIR, HLA, and β 2 -microglobulin recombinant proteins were refolded (18) , and cocrystals of KIR2DS2-*001 and -A*11:01 bound to the vaccinia virion membrane protein A14-derived peptide MLIYSMWGK (Immune Epitope Database and Analysis Resource, Epitope ID 41975; www.iedb.org/ assay_details.php?assayId=1359384) were successfully generated and its structure was determined to 2.5-Å resolution ( Fig. 1 A and B and Table 1 ). The molecular packing resulted in two KIR2DS2-HLA-A*11:01 complexes in one asymmetric unit in a "head-to-tail" arrangement, and contact with the complex can be observed between the D2 domain of KIR2DS2 and N terminus of the peptide-binding grove of the heavy chain ( Fig. S1 A and B and ). Comparing the hinge angle of the free KIR2DS2 (19) with that of the Significance Killer cell immunoglobulin-like receptors (KIRs) function as key recognition elements in innate immunity. Structural information for inhibitory KIRs 2DL2, 2DL1, and 3DL1 in complex with their respective HLA ligands is available, but such data for activating KIRs are lacking. We report here the successful crystallization and solved structure of the activating KIR2DS2 in complex with HLA-A*11:01. The structure clearly explains the role of Tyr45, which has long puzzled KIR researchers because it differentiates KIR2DS2 from all inhibitory KIRs, and is now shown to bind Thr80 of HLA-A*11:01. Using KIR2DS2 tetramers to bind HLA on live cells, we also provide evidence that peptide sequence can affect KIR-HLA binding. Our data thus resolve a long-standing problem in KIR biology.
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complexed KIR2DS2, there is only a small expansion of the hinge angle induced by the binding from 71.2°to 72.4° (Fig. 1C) . However, after superimposing HLA molecules of different HLA-KIR complexes, the relative orientations of the D1 and D2 domains displayed significant differences. The D1 and D2 domain axes of KIR2DS2-HLA-A*11:01 differ from those of KIR2DL1-HLA-C*04:01 by 10.6°and 8.5°, respectively (Fig. 1D) . A more significant D1 axis difference of 25.8°was observed between KIR2DS2-HLA-A*11:01 and KIR2DL2-HLA-C*03:04, whereas the D2 axis remained similar. The consequence of this D1 orientation in KIR2DS2 results in the shift of the CC′ loop toward the C-terminal region of the HLA α1-helix. The CC′ loop of the D1 domain, hinge region, and BC and FG loops in the D2 domain of KIR2DS2 are the main contact points with the HLA α1-and α2-helical regions ( Fig. 2 A and B and Fig. S2 ). The CC′ loop of KIR2DS2 was observed to be positioned more toward the C terminus of the α1-helix of HLA-A*11:01, and this displacement was 2.6 Å compared with KIR2DL1 ( Fig. 2A) and an even more significant difference of 6.2 Å compared with KIR2DL2 (Fig.  2B ). In KIR2DL2, residue Phe45 located at the tip of the CC′ loop is inserted into the groove of the α1-helix of HLA residues 75-80 and is surrounded by atoms through hydrophobic interactions (Fig. 2C) . However, Tyr45 of KIR2DS2 shifts toward the C terminus of the α1-helix, allowing it to contact the NH group of HLA Thr80 to form a hydrogen bond (Fig. 2C) .
The conserved interdomain salt bridge Asp98-Arg149 present in all inhibitory KIR molecules is not observed in KIR2DS2. For inhibitory KIRs, this salt bridge is disrupted by conformational change when the KIR binds to HLA and contributes to the increase in the interdomain hinge angle of the complexed KIR2DL2. With KIR2DS2, the Nη1 and Nη2 groups of Arg149 are >8 Å away from the carboxyl groups of Asp98 in its free form and narrow slightly to 5.5 and 5.9 Å, respectively, after binding to HLA-A*11:01. Pro16 in the KIR2DS2 D1 domain, which in KIR2DL1/ 2DL2 is Arg16, lies at the interdomain interface, and this difference in side-chain volume may also contribute to the shaping of the hinge angle.
Shape complementarity for the interface of KIR2DS2 and HLA-A*11:01 showed a calculated mean value of shape correlation statistic of 0.64 and suggests that molecular bond formation contributes significantly to the binding interaction. Of these, the most important appears to be formation of salt bridges (KIR-HLA: Asp72-Arg75, Asp135-Arg145, Glu187-Lys146) and hydrogen bonds (KIR-HLA: Tyr45-Thr80, Glu106-Ala149, Ser133-Arg145, Ser184-Lys146). A comparison with the inhibitory KIR2DL1-HLA-C*04:01 and KIR2DL2-HLA-C*03:04 structures shows the use of Tyr45, Asp72, Tyr134, and Glu87 in KIR2DS2 to create new interactions that contribute to its binding specificity with A*11:01 (Table S2) .
The footprint of the interaction on the A*11:01 surface shows the area on the α1-helix surface comprising Gln72, Arg75, Val76, Values in parentheses refer to the highest-resolution shell. AU, asymmetric unit.
R free is the same as R cryst and is calculated on 5% of the data excluded from refinement.
Gly79, Thr80, Arg82, and Gly83 to make contact with D1 of KIR2DS2 (Fig. 2 E-G) . Specifically, hydrogen bonds between the D1 domain and HLA α1-helix at Asp72-Arg75 and Tyr45-Thr80 were observed (Table S3 ). The D2 domain engages the HLA α2-helix across a larger number of residues including Ile142, Arg145, Lys146, Ala149, Ala150, and His151.
NMR Titration of the KIR-HLA Interaction. With the availability of the solved crystal structure, we sought to confirm these observations using an alternative approach, and examined the KIR2DS2-HLA-A*11:01 binding interactions using transverse relaxation-optimized spectroscopy-heteronuclear single quantum coherence (TROSY-HSQC), which is a highly sensitive method of assigning positions of specific atoms and determining chemical shifts indicative of binding interactions (Fig. 3 and Fig. S3 ). Tyr45 is unique to KIR2DS2, and it has been proposed that KIR2DS2 evolved away from binding the HLA-C1 epitope by substitution of Phe45 with Tyr45 (16, 17) . The importance of position 45, illustrated by a swap from Tyr45 to Phe45, is sufficient to restore some binding (although not to the same degree as KIR2DL2) with the Lys80 C1 epitope (17) . In the KIR2DS2-A*11:01 structure, the Tyr45 side chain orients toward the α1-helix and hydrogen-bonds with the Thr80 backbone NH group. NMR analysis showed a chemical shift change at Tyr45 when HLA-A*11:01 was titrated into the KIR2DS2 sample (Fig. 3C′) , thus confirming its role in KIR2DS2 binding. An interesting feature to be tested is position 44 of KIR2DS2, which in inhibitory KIRs determines the dimorphic binding characteristic between the C1 and C2 epitopes of HLA-C (16, 20) . From the NMR and structural data, Lys44 can be seen to have only a weak hydrophobic interaction with Ala83 (Fig. 3B′) , and thus appears to have a diminished role in KIR2DS2 compared with the inhibitory KIRs.
KIR3DL2 and KIR2DS4 have been reported to bind A*11 and that Lys44, Pro71, and Val72 are important for this interaction (15, 16) . Position 71 in KIR2DS2 is Gln71 and shows polar interaction with the Val76 backbone of A*11:01 (Fig. 3D) . Similar to the structure of KIR2DL2-C*03:01, the tip of KIR2DS2 Gln71 interacts with p8 of peptide bound to HLA-A*11:01, indicating the potential role of peptide in recognition of HLA-A*11:01 by KIR2DS2. Only a slight chemical shift change was observed in the NMR titration experiment, which is consistent with an overall moderate binding interaction (Fig. 3D′) . Asp72 of KIR2DS2 hydrogen-bonds with Arg75 of HLA-A*11:01 (Fig. 3E) , and this KIR-HLA interaction has not been described previously in inhibitory KIR binding. The TROSY-HSQC spectrum detects a strong chemical shift signature for Asp72 and supports the nature of this binding interaction (Fig. 3E′) .
The salt bridge Ser133/Asp135-Arg145 and hydrogen bond Glu106-Ala149/His151 (Fig. 3 F, G , F′, and G′) conserved in inhibitory KIRs can also be seen in KIR2DS2-HLA-A*11:01, and this represents the retained homology between KIR2DS2 and the inhibitory KIRs. Interestingly, a hydrogen bond that is usually formed between Asp183 of inhibitory KIRs and Lys146 of HLA is now made by Ser184 of KIR2DS2 (Fig. 3 H and H′) . This slight change to accommodate a subtle shift in the FG loop preserves the hydrogen bond, which is important for maintaining the overall integrity of the KIR-HLA complex.
Tetramer Staining Assay of KIR2DS2-HLA-A*11:01 Binding in Live Cells. To demonstrate whether KIR2DS2-HLA-A*11:01 binding occurs in live cells, KIR2DS2 tetramers were generated (SI Materials and Methods). The lymphoblastoid cell line BM03, homozygous for HLA-A11, was first tested to confirm expression of surface HLA-A11 using an A11-specific antibody (4i93; Abcam), whereas MF2, an HLA-A11-null cell line, and the MHC class I mutant 721.221 were both negative for HLA-A11 expression (Fig. S4 A-C) . Using KIR2DS2 tetramers, BM03 showed strong staining when pulsed with 250 μg of the MLIYSMWGK peptide (WGK; Fig. S4D ), whereas MF2 and 721.221 remained negative in the presence of the peptide as well as three other peptide variants, MLIYSM-WAK (WAK), MLIYSMWSK (WSK), and MLIYSMWVK (WVK) (Fig. S4 E and F) . Because tetramer staining is highly sensitive, it can be used to assess the impact of peptide on KIR-HLA binding. To do so, peptides with different side-chain volume residues at p8, Gly, Ser, Ala, Thr, Val, and Trp, as well as those with charged residues, Asp, Glu, Lys, and Arg, were synthesized. Interestingly, the replacement of Gly with Ser, Ala, Thr, Val, or Trp at the p8 position still permits the association between KIR2DS2 and HLA-A*11:01 (Fig. S4G) . However, the presence of charged residues at p8 of the peptide uniformly resulted in loss of binding (Fig. S4H) . In addition to the peptide sequence, binding is also influenced in a peptide dose-dependent manner (Fig. S4 I-N) . Taken together, the cell-based tetramer binding assays demonstrate that KIR-HLA binding is not entirely peptide-agnostic.
Mutational Analysis of KIR2DS2-Binding Contact Residues. Using a surface plasmon resonance (SPR) assay, the binding interaction between KIR2DS2 and A*11:01 was first determined in triplicate, showing a K D of ∼22 μM (Fig. 4 A and C-F) . HLA-C controls C*08:01, and C*12:02 confirmed the lack of interaction between KIR2DS2 and HLA-C molecules (Fig. S5 A and B) . Mutational analysis was carried out on all important contact residues of KIR2DS2 to verify their roles in providing stability to the KIR-HLA complex (Fig. 4 A, B , and G-P). Alanine mutants at positions 45, 71, 72, 104, 106, 135, 184, and 187 abrogated KIR-HLA binding, which confirmed the observations with inhibitory KIRs that a single amino acid change at a critical position can completely disrupt binding. An A11-binding motif (21, 22) comprising Pro71/Val72 was previously reported, and this was tested with a double mutation that changed Gln71/Asp72 of KIR2DS2 to Pro71/Val72. However, this did not result in any binding, which suggests that the Pro71/Val72 combination could function in the context of KIR2DS4 or KIR3DL2 but not necessarily in other KIRs such as KIR2DS2.
The mutants Lys44Ala, Tyr134Ala, and Tyr45Phe resulted in some loss of measurable binding, but this was insufficient to disrupt the overall stability of the KIR-HLA complex, which suggests that such disruption is compensated by the network of salt bridges and other hydrogen bonds that keep the binding intact. However, a Tyr45Ala mutation abrogated binding, suggesting that Ala is a more drastic change at this position than Phe, which is of the same aromatic amino acid grouping as Tyr (Fig. 4 A, M, and N) . Hence, position 45 appears to be important to maintain the stability of KIR2DS2-HLA-A*11:01 binding given that alanine mutation abrogated binding whereas a similar mutation at the adjacent position 44 did not. The binding experiments were performed with both A*11:01 and A*11:02, which differ only at one amino acid (Glu19Lys), and both HLA alleles showed similar binding behavior to KIR2DS2. A*11:02 therefore provided a functional and validating replicate for the SPR binding studies.
Discussion
The main HLA ligand specificities for inhibitory KIRs are HLA-C (23, 24) ; however, the activating KIR2DS2 does not bind well to HLA-C. Although these observations have not been formally proven using crystal structure data, amino acid substitution experiments have shown that replacement of tyrosine at position 45 alone of KIR2DS2 can restore some degree of binding activity with HLA-C. Although tantalizing, these results do not explain the mechanism behind the loss of binding with HLA-C and which specific residues of HLA are likely to engage with position 45 of KIR2DS2. In this study, we provide structural evidence that the activating KIR2DS2 binds to a previously unrecognized HLA ligand, A*11:01. In addition, the use of NMR and HSQC titration provides further confirmation of binding interactions by tracing chemical shift changes of specific residues.
In contrast with inhibitory KIRs, the role of position 44 in the activating KIR2DS2 is greatly diminished. The lack of significant binding interaction of position 44 is a major departure from its known function in inhibitory KIRs, and SPR data show that substitution of Lys44 with Ala does not result in a significant decline in binding. Of interest is position 45, which is a residue unique to KIR2DS2, and because no prior evidence has been shown that Tyr45 has a specific function, it has been speculated to constitute a "fatal" mutation (17) and that it has been actively selected to lose binding with HLA class I (8, 16) . We found that Tyr45 has an important role in forming hydrogen bonds with the backbone of Thr80 of HLA. It does so by being positioned closer to the C terminus of the α1-helix, whereas in inhibitory KIRs, Phe45 is accommodated by the helix groove comprising the HLA-A*11:01 75-80 fragment through hydrophobic contacts. Mutating Tyr45 to Phe45 resulted in some loss of binding but was not abrogated completely, whereas an Ala45 mutant showed no binding. This suggests that position 45 plays an important role in maintaining the stability of the KIR2DS2-HLA-A*11:01 interaction.
The KIR2DS2-HLA-A*11:01 structure has revealed binding interactions that differ from those seen in inhibitory KIRs; these are the salt bridges Asp72-Arg75 and Glu187-Lys146, hydrogen bond Tyr45-Thr80, and hydrophobic interactions Tyr134-A149. Interestingly, KIR2DS4 has previously been shown to exhibit A*11:01 and A*11:02 binding specificity by means of a Pro71/ Val72 motif at the D1 domain (22) . Human KIR2DS4 shares this Pro71/Val72 motif with KIR3DL2, and is believed to have arisen (25) . (A) Site-directed mutagenesis of specific amino acids was separately generated for KIR2DS2: P16A, K44A, Y45F, Y45A, Q71K, D72A, L104A, E106A, Y134A, D135A, S184A, and E187A were single mutants, whereas Q71P/D72V was a double mutant. Each interaction was assayed in at least two independent experiments, whereas the WT was tested in four independent experiments. through a gene conversion event between the ancestral lineages of these two genes. KIR2DS4-Fc fusion proteins have shown binding to A*11:02 and to a lesser extent A*11:01, but the interacting residues between KIR and HLA have also not been formally proven. In KIR2DS2, Asp72 does not follow the binding interactions proposed for Val72 binding to KIR2DS4, because substitution of Asp72 with Val results in a loss of binding. Nevertheless, KIR2DS2 and KIR2DS4 have many residue differences such that Val72 may be relevant only to KIR2DS4. Our data show, however, that position 72 is an important residue (more so than position 44), and may be a binding paradigm for activating KIRs. Gln71 in KIR2DS2 does not participate in strong bond formation as with Asp72, but it is sufficiently close to being able to interact with p8 of the peptide. It appears that in inhibitory KIRs (26) (27) (28) , bulky or strongly charged residues are likely to affect the overall KIR-HLA interaction.
In this study, the availability of structural information, live-cell tetramer staining, NMR, and SPR binding data together provides insight into the binding of activating KIR2DS2 to HLA-A*11:01 as its cognate ligand. Furthermore, the role of peptide sequence is demonstrated by altered KIR2DS2-tetramer binding when the peptide p8 residues are charged residues, and therefore lends understanding to how minimal amino acid changes can dramatically alter binding characteristics of highly homologous inhibitory KIRs. The identification of the unique network of critical residues in determining the binding specificity of activating KIRs and the mediation of peptide in KIR-HLA association will be the basis for future work on how KIRs are activated and their mechanism of action.
Materials and Methods
Full details of the methods are described in SI Materials and Methods. Briefly, single-wavelength native data of the KIR2DS2-HLA-A*11:01 crystal were collected with space group P2 1 2 1 2 1 with unit cell parameters a = 69.5, b = 94.7, c = 228.4, α = β = γ = 90°and further processed using CCP4 (29) . Rigid-body and restrained refinement were performed using REFMAC5 (30) . Model geometry of the complex was verified with PROCHECK (31), and PDBePISA (32) was used to generate interface data. The structure coordinates have been deposited in the Protein Data Bank under PDB ID code 4N8V.
